Research progress in venetoclax and its combined medication in treatment of acute myeloid leukemia
The incidence rate of acute myeloid leukemia(AML)is increased with age increase,the older the age,the worse the prognosis,there is a certain correlation between the two.In the last few decades,the standard treatment scheme for the AML patients has no significant change,moreover the survival rate in the patients with senile,recurrent and refractory AML has no significant improvement.B cell lymphoma 2(Bcl-2)is a key regulator of mitochondrial apoptosis pathway and plays a key role in the apoptosis of tumor cells.Venetoclax(Ven)is the first commercially available Bcl-2 inhibitor.Its monotherapy for treating AML has a good safety.However,compared with the combination of other chemotherapeutic regimens,its single drug ef-ficacy is relatively limited and easy to produce drug resistance,and the combined medication scheme has grad-ually become a treatment trend.In recent years,it has been found that VEN-based induction chemotherapiutic regimen has significant efficacy and better safety than traditional chemotherapic regimens.The emergence of Ven may change the treatment pattern of AML patients,especially the patients with relapsed/refractory AML and elderly AML patients who are not suitable for intensive chemotherapy.This article reviews the research progress of Bcl-2 inhibitor Ven combined with other chemotherapeutic drugs in the treatment of AML pa-tients.
国家科技期刊平台
NSTL
万方数据
